New therapies harness power of the immune system against cancer

Striking results of investigative immunotherapies for melanoma and cervical cancer highlighted

2014-06-02

(Press-News.org) CHICAGO – New research on innovative immunotherapies for advanced or high-risk melanoma and cervical cancer were presented today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). These treatments – used alone or in combination – fight cancer by activating and amplifying the body's immune response to the disease.

The new studies find high activity with investigative drugs for advanced melanoma, and show for the first time that ipilimumab, a treatment already approved for advanced melanoma, can substantially decrease the risk of melanoma recurrence in certain patients with earlier-stage disease. In addition, another small trial reports that a one-time, personalized immunotherapy treatment induces complete and long-lasting remissions in a small number of women with advanced cervical cancer – a disease with little to no effective treatment options.

"The field of immunotherapy has exploded in the last decade, and more and more patients are benefiting," said press briefing moderator Steven O'Day, MD, ASCO expert and clinical associate professor of medicine at the University of Southern California, Keck School of Medicine. "Having a potential new way to keep melanoma at bay is a major advance for patients who live under the constant fear of recurrence after surgery. It's also incredibly exciting that we're extending the benefits of immunotherapy beyond melanoma, to diseases like cervical cancer where patients urgently need better options."

Featured studies include:

Adjuvant ipilimumab improves recurrence-free survival in patients with high-risk stage III melanoma: Study marks the first time adjuvant (post-surgery) ipilimumab is shown to be effective in earlier-stage melanoma, though side effects are considerable.

PD-1 targeting immunotherapy MK-3475 has high and long-lasting activity against metastatic melanoma: Large phase I trial finds high survival rates in patients with advanced melanoma, including those previously treated with ipilimumab; one-year survival rate is 69 percent across all patient subgroups. Combination immunotherapy with ipilimumab and nivolumab achieves long-term survival for patients with advanced melanoma: Updated follow-up data from an expanded phase I study show concurrent treatment with ipilimumab and the anti-PD-1 nivolumab yields strong, long-lasting responses and high survival rates.

HPV-targeted adoptive T cell therapy may provide a new personalized strategy for advanced cervical cancer: Early study of HPV-targeted immunotherapy shows promising activity in metastatic cervical cancer, a hard-to-treat disease with few effective treatment options. INFORMATION: Media Resources:

Online Annual Meeting Media Resource Center: Visit http://www.asco.org/AMMRC for press releases, press briefing recordings, the press briefing schedule at-a-glance, embargo policies, high-resolution photos, print-friendly downloads, and the Virtual Press Room, an online repository of corporate and institutional press releases from third-party organizations.

CancerProgress.Net: The home of ASCO's 50th Anniversary and a timeline detailing the progress made against 18 of the most common cancers.

Cancer.Net: ASCO's cancer information website, providing doctor-approved information on more than 120 cancer types.

The Annual Meeting Media Resource Center will be updated frequently leading up to and throughout the Annual Meeting.

ATTRIBUTION TO THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY ANNUAL MEETING IS REQUESTED IN ALL NEWS COVERAGE.

Click here to view the disclosures for the 2014 ASCO Annual Meeting News Planning Team.

About ASCO Founded in 1964, the American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who care for people with cancer. With nearly 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit http://www.asco.org. Patient-oriented cancer information is available at http://www.cancer.net.

ELSE PRESS RELEASES FROM THIS DATE:

Doing more with less; in cellulo structure determinations

2014-06-02

Anyone involved in macromolecular crystallography will know that for many years scientists have had to rely on a multi-stage process utilizing protein, usually expressed in engineered cells, which is then extracted and purified before crystallization in vitro and finally prepared for analysis. As a counter to this time-consuming and substantial scientific effort, there are a number of examples of protein crystallization events occurring in vivo, with next to no human input. In a case presented in a recent paper an insect virus exploits the phenomenon as part of its life ...

BRCA2 gene now connected to lung cancer, doubling a smoker's risk

2014-06-02

New research confirms a vulnerability to lung cancer can be inherited and implicates the BRCA2 gene as harboring one of the involved genetic mutations. An international consortium of scientists including investigators at the Institute for Cancer Research in London, the International Agency for Research on Cancer in Lyon, the National Cancer Institute in Bethesda, Harvard, and Dartmouth used integrated results from the 1000 Genomes Project with genetics studies of lung cancer to complete the investigation published on June 1, 2014 in Nature Genetics. The study scanned ...

Transforming hydrogen into liquid fuel using atmospheric CO2

2014-06-02

Hydrogen is often touted as the fuel of the future. But because this gas is highly explosive, it must be stored and transported under pressure in specialized and expensive containers. Hydrogen therefore has issues in terms of safety, logistics, and profitability that could significantly limit its wider use. However, a solution might lie in research by EPFL scientists, who have developed a simple system based on two chemical reactions. The first reaction transforms hydrogen into formic acid, a liquid that is easy to store and less flammable than gasoline, while the second ...

Small businesses less likely to offer health promotion programs

2014-06-02

Employees at small businesses are less likely to have access to worksite wellness programs, according to a research review in the May Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine (ACOEM). But smaller companies that can overcome the barriers and implement wellness programs can realize achieve meaningful improvements in employee health, report Kira McCoy, BA, of Hampshire College, Amherst, Mass., and colleagues. They write, "Preventative health initiatives and disease management ...

CPAP rapidly improves blood pressure and arterial tone in adults with sleep apnea

2014-06-02

DARIEN, IL – A new study suggests that continuous positive airway pressure (CPAP) therapy rapidly improves blood pressure and arterial tone in adults with obstructive sleep apnea (OSA). Results show that there was a significant reduction in systolic and diastolic blood pressures among sleep apnea patients who were compliant with CPAP therapy for three months. Successful treatment of sleep apnea also was associated with decreased vascular tone and arterial stiffness. Following one week of treatment withdrawal, these improvements disappeared and reverted to baseline values. "We ...

Studies reveal new strategies to improve quality of life

2014-06-02

CHICAGO – Key studies released today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) identify new strategies for easing the short- and long-term effects of cancer therapy and improving the quality of life of patients with cancer, as well as their caregivers. "We've made incredible strides in cancer treatment, and more cancer survivors are alive today than ever before. But oncology isn't just about helping people live longer – we need to ensure that patients have the best quality of life possible at every stage of their cancer journey, from ...

Studies reveal potential new targeted therapies for common, hard-to-treat cancers

2014-06-02

CHICAGO – Positive results from four clinical trials of investigational targeted drugs for advanced ovarian, lung, and thyroid cancers, and chronic lymphocytic leukemia were highlighted today at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO). Findings from the mid- and late-stage trials suggest new ways to slow disease progression and improve survival for patients who experience relapses or resistance to available treatments. "Cancer relapses and treatment resistance have always been among the most daunting challenges in cancer care," said ...

Clinical trial shows drug combination may be highly effective in recurrent ovarian cancer

2014-06-02

VIDEO: Dr. Joyce Liu talks about her ovarian cancer research at ASCO 2014. Click here for more information. CHICAGO –– Significant improvement with the use of a combination drug therapy for recurrent ovarian cancer was reported at the annual meeting of the American Society of Clinical Oncology (ASCO) meeting in Chicago today. This is the first ovarian cancer study to use a combination of drugs that could be taken orally. The drugs were tested in a phase I combination study followed ...

Drug combination extends survival by more than a year in metastatic prostate cancer

2014-06-02

VIDEO: Dr. Christopher Sweeney talks about his new study showing a drug combination extends survival by more than a year in metastatic prostate cancer. Click here for more information. CHICAGO – Men with newly diagnosed metastatic, hormone-sensitive prostate cancer lived more than a year longer when they received a chemotherapy drug as initial treatment instead of waiting to for the disease to become resistant to hormone-blockers, report scientists from Dana-Farber Cancer Institute ...

Prostate cancer drug delivers benefits before chemotherapy

2014-06-02

PORTLAND, Ore. – A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national Phase III clinical trial led by the Knight Cancer Institute at Oregon Health & Science University (OHSU). A comprehensive analysis of the study's results ― published in June 1 online edition of the New England Journal of Medicine and to be presented at the American Society of Clinical Oncology (ASCO) annual ...

New therapies harness power of the immune system against cancer

ELSE PRESS RELEASES FROM THIS DATE:

LAST 30 PRESS RELEASES: